News summary

Innogen Pharmaceuticals Enters into Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa, Accelerating International Expansion

Source: PR Newswire • Published: 19 Nov 2026, 10:05

Summarized by Masters of Longevity from PR Newswire.

Innogen granted Arcera exclusive rights to efsubaglutide alfa in select regions.

Innogen Pharmaceuticals Enters into Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa, Accelerating International Expansion
Key Takeaways
  • Arcera obtained exclusive rights in Africa, Latin America, Middle East.
  • Innogen will receive US$38 million upfront and near-term milestones.
  • Clinical studies showed weight loss and HbA1c reductions in trials.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?